Wuxi Bio (Suzhou) Co., Ltd. submitted its securities change monthly report as of June 30, 2024 to Hong Kong Exchanges and Clearing Limited on July 4, 2024. The report shows that the company's statutory/registered share capital balance remains at 6 billion US dollars, with a face value of USD1/120,000 per share, totaling 50,000 US dollars. The issued shares (excluding treasury shares) decreased from 4,262,481,929 shares at the end of last month to 4,153,165,949 shares, a decrease of 109,315,980 shares. This change was mainly due to the company's repurchase and cancellation of 109,868,000 ordinary shares at a price of HKD21.31 per share on June 11, 2024, as well as the repurchase of 1,810,000 ordinary shares that have not yet been canceled on the same day. In addition, the report also mentioned the exercise situation under the share options plan, and the share awards granted under the restricted share awards plan and the global partner plan. All securities issuance or treasury stock sales or transfers have been approved by the board of directors and comply with all applicable listing rules, laws and other regulatory requirements.

Wuxi Bio (Suzhou) Co., Ltd. submitted its securities change monthly report as of June 30, 2024 to Hong Kong Exchanges and Clearing Limited on July 4, 2024. The report shows that the company's statutory/registered share capital balance remains at 6 billion US dollars, with a face value of USD1/120,000 per share, totaling 50,000 US dollars. The issued shares (excluding treasury shares) decreased from 4,262,481,929 shares at the end of last month to 4,153,165,949 shares, a decrease of 109,315,980 shares. This change was mainly due to the company's repurchase and cancellation of 109,868,000 ordinary shares at a price of HKD21.31 per share on June 11, 2024, as well as the repurchase of 1,810,000 ordinary shares that have not yet been canceled on the same day. In addition, the report also mentioned the exercise situation under the share options plan, and the share awards granted under the restricted share awards plan and the global partner plan. All securities issuance or treasury stock sales or transfers have been approved by the board of directors and comply with all applicable listing rules, laws and other regulatory requirements.